Market Place
Sourcing Support
Synaptogenix Announces $5.0 Million Financing
11 Sep 2024 //
PR NEWSWIRE
Synaptogenix Partners With LSU For Spinal Cord Injury Study
18 Jul 2024 //
PR NEWSWIRE
Synaptogenix Gets FDA IND Authorization For Bryostatin-1 In Multiple Sclerosis
26 Jun 2024 //
PR NEWSWIRE
Synaptogenix On DEA Cannabis Reclassification For Drug Discovery
07 May 2024 //
PR NEWSWIRE
Synaptogenix Regains Nasdaq Minimum Bid Compliance
24 Apr 2024 //
PR NEWSWIRE
Synaptogenix Increases Psilocybin Discovery Stake Via Cannasoul
09 Apr 2024 //
PR NEWSWIRE
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
03 Apr 2024 //
PR NEWSWIRE
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation
19 Dec 2023 //
PR NEWSWIRE
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker
06 Dec 2023 //
PR NEWSWIRE
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd.
02 Nov 2023 //
PR NEWSWIRE
Synaptogenix Announces Publication of NIH-Sponsored Phase 2 Clinical Trial
26 Sep 2023 //
PR NEWSWIRE
Bryostatin-1 from Synaptogenix Shows Significant Results as an ALS Treatment
07 Sep 2023 //
PR NEWSWIRE
Synaptogenix & Cleveland to Submit IND Application for Trial of Bryostatin-1
19 Jul 2023 //
PR NEWSWIRE
Synaptogenix Abstract Shows Bryostatin-1 Benefits Accepted for Presentation
13 Jul 2023 //
PR NEWSWIRE
Synaptogenix Provides Update and Outlines Potential Business Opportunities
07 Mar 2023 //
PR NEWSWIRE
Alzheimer`s fail crushes small biotech`s share price to nearly penny stock
19 Dec 2022 //
ENDPTS
Alzheimer`s fail crushes small biotech`s share price to nearly penny stock
19 Dec 2022 //
ENDPTS
Synaptogenix`s Alzheimer`s prospect flops in NIH-sponsored study
16 Dec 2022 //
FIERCEBIOTECH
Synaptogenix Announces Topline Results from PII Trial of Bryostatin-1
16 Dec 2022 //
PRNEWSWIRE
Synaptogenix Announces $15 Million Private Placement with Existing Investors
18 Nov 2022 //
PRNEWSWIRE
Synaptogenix Announces Live Appearance of its President and CSO
12 Aug 2022 //
PRESS RELEASE
Investor pleads guilty to insider trading in Alzheimer`s biotech
28 Jul 2022 //
FIERCEBIOTECH
Synaptogenix Announces Changes to Scientific Advisory Board
26 Jul 2022 //
PRNEWSWIRE
Synaptogenix Announces Corporate Update Conference Call
21 Jul 2022 //
PRESS RELEASE
Synaptogenix Advances Dosing in Dose Optimization Clinical Trial in Preparation
20 Jul 2022 //
PRNEWSWIRE
Synaptogenix to Present at the Cell Symposium
17 May 2022 //
PRNEWSWIRE
Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Declines By 20.7%
03 May 2022 //
DEFENSE WORLD
Synaptogenix Completes Patient Enrollment in NIH Sponsored PIIb AD Trial
19 Apr 2022 //
PRESS RELEASE
Extended Therapeutic Potential of Synaptogenix`s Bryostatin for AD
05 Apr 2022 //
PRNEWSWIRE
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
29 Mar 2022 //
PRESS RELEASE
Synaptogenix to Present Research Highlights for Lead Compound Bryostatin
15 Mar 2022 //
PRESS RELEASE
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1
23 Feb 2022 //
PRESS RELEASE
Synaptogenix Positive Results of Further Bryostatin Trial Analyses AAIC 2021
26 Jul 2021 //
PRNEWSWIRE
Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings
21 Jul 2021 //
PRNEWSWIRE
Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer`s Disease
07 Jul 2021 //
PR NEWSWIRE
Synaptogenix Announces $12.5 Million Private Placement
14 Jun 2021 //
BIOSPACE
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer`s Disease Trial Update
09 Jun 2021 //
PRNEWSWIRE
Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update
01 Apr 2021 //
PRNEWSWIRE
Synaptogenix Announces $14.0 Million Private Placement
21 Jan 2021 //
PRNEWSWIRE
